References
- Abraham, H. D., & Aldridge, A. M. (1993). Adverse consequences of lysergic acid diethylamide. Addiction (Abingdon, England), 88(10), 1327–1334. doi:10.1111/add.1993.88.issue-10
- Ahrnsbrak, R., Bose, J., Hedden, S. L., Lipari, R. N., & Park-Lee, E. (2017). Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. Rockville, MD, USA: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. 7(1), 877.
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
- Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. doi:10.1177/0269881114565144
- Cottler, L. B., Leung, K. S., & Abdallah, A. B. (2009). Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: A cross-national study. Addiction (Abingdon, England), 104(10), 1679–1690. doi:10.1111/j.1360-0443.2009.02649.x
- Cottler, L. B., Womack, S. B., Compton, W. M., & Ben-Abdallah, A. (2001). Ecstasy abuse and dependence among adolescents and young adults: Applicability and reliability of DSM-IV criteria. Human psychopharmacology, 16(8), 599–606. doi:10.1002/hup.343
- Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016). Lysergic acid diethylamide: A drug of “use”? Therapeutic Advances in Psychopharmacology, 6(3), 214–228. doi:10.1177/2045125316640440
- De Gregorio, D., Comai, S., Posa, L., & Gobbi, G. (2016). d-Lysergic Acid Diethylamide (LSD) as a model of psychosis: Mechanism of action and pharmacology. International Journal of Molecular Sciences, 17, 11. doi:10.3390/ijms17111953
- Gable, R. S. (1993). Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. The American Journal of Drug and Alcohol Abuse, 19(3), 263–281. doi:10.3109/00952999309001618
- Glennon, R. A., Titeler, M., & McKenney, J. D. (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences, 35(25), 2505–2511. doi:10.1016/0024-3205(84)90436-3
- Gresch, P. J., Strickland, L. V., & Sanders-Bush, E. (2002). Lysergic acid diethylamide-induced Fos expression in rat brain: Role of serotonin-2A receptors. Neuroscience, 114(3), 707–713. doi:10.1016/S0306-4522(02)00349-4
- Klock, J. C., Boerner, U., & Becker, C. E. (1975). Coma, hyperthermia, and bleeding associated with massive LSD overdose a report of eight cases. Clinical Toxicology, 8(2), 191–203. doi:10.3109/15563657508988063
- Krebs, T. S., & Johansen, P.-Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994–1002. doi:10.1177/0269881112439253
- Liester, M. B. (2014). A review of lysergic acid diethylamide (LSD) in the treatment of addictions: Historical perspectives and future prospects. Current Drug Abuse Reviews, 7(3), 146–156. doi:10.2174/1874473708666150107120522
- Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131–181. doi:10.1016/J.PHARMTHERA.2003.11.002
- Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics, 14(4), 295–314. doi:10.1111/j.1755-5949.2008.00059.x
- Ross, S. (2012). Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatric Clinics of North America, 35(2), 357–374. doi:10.1016/j.psc.2012.04.002
- Schwartz, R. H., Comerci, G. D., & Meeks, J. E. (1987). LSD: Patterns of use by chemically dependent adolescents. The Journal of Pediatrics, 111(6), 936–938. doi:10.1016/S0022-3476(87)80223-8
- Smart, R. G., & Bateman, K. (1967). Unfavourable reactions to LSD: A review and analysis of the available case reports. Canadian Medical Association Journal, 97(20), 1214–1221.
- Smith, D. E., Raswyck, G. E., & Dickerson Davidson, L. (2014). From hofmann to the haight ashbury, and into the future: The past and potential of lysergic acid diethlyamide. Journal of Psychoactive Drugs, 46(1), 3–10. doi:10.1080/02791072.2014.873684
- Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Bäbler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport, 9(17), 3897–3902. doi:10.1097/00001756-199812010-00024